Sutro Biopharma, Inc. (STRO) recently garnered favorable attention from David Nierengarten of Wedbush, who upgraded the company’s rating to “Outperform” on May 15, 2026. This upgrade aligns with a price target of $60, well above the current trading price of $38.97, signaling strong upside potential for investors. Such positive sentiment amid volatile market conditions raises interest in Sutro Biopharma as a potential investment opportunity.
Recent Price Action
STRO has seen notable activity in recent trading sessions, closing at $38.97 with a slight increase of $0.55, representing a gain of approximately 1.43%. The stock experienced a trading volume of 261,199, surpassing its average volume of 210,446, indicating heightened investor interest. However, the stock’s beta of 1.64 suggests increased volatility compared to the broader market, which could raise concerns for conservative investors. With a 52-week high yet to be established, the low end of its trading over the past year sat at $291.32, illustrating the stock’s tumultuous journey.
[chart type=’price’ value=’STRO’]
Historical Performance
Examining Sutro Biopharma’s performance over various time frames reveals mixed results. Over the past 30 days, the stock has surged by 63.42%, highlighting a strong recent recovery. Quarterly performance reflects a robust increase of 47.72%, aligning with the improvement in sentiment following the recent upgrade. However, on a year-over-year basis, the stock’s performance shows a decline of 19.35%. This disparity may reflect inherent market pressures or company-specific challenges. The stock’s weekly volatility stands at 12.39%, while monthly volatility is slightly lower at 10.48%, suggesting a measure of risk that investors should consider.
[chart type=’performance’ value=’STRO’]
Earnings Analysis
In terms of earnings performance, Sutro Biopharma recently reported an earnings per share (EPS) of -$2.94, which exceeded the estimated EPS of -$2.7363 by 7.44%. This positive surprise, somewhat counterintuitive in a negative EPS context, indicates the company is managing expectations well, which may boost investor confidence. In the previous quarter, the company’s actual EPS was significantly lower at -$5.29 against an estimate of -$8.16266, leading to a negative surprise factor of -35.19%. Such fluctuations highlight the company’s challenges in maintaining profitability but suggest improved management projection and potentially stabilizing performance.
[chart type=’income-bar-chart’ value=’STRO’]
Analyst / Consensus View
The sentiment surrounding Sutro Biopharma is overwhelmingly positive, with a total of eight analysts providing ratings — all classified as “Buys,” resulting in a 100% consensus with no holds or sells noted. The average price target across these analysts stands at $43.25, while the high price target maintains the optimistic forecast of $60 as suggested by Wedbush’s Nierengarten. These ratings and price targets signal strong analyst confidence, reflecting both short-term recovery potential and long-term growth prospects.
[chart type=’analyst-ratings’ value=’STRO’]
Stock Grading and Fundamental View
The Stocks Telegraph Grade, or ST Score, for Sutro Biopharma is recorded at 44. This score synthesizes various financial health and market analysis metrics, indicating room for improvement but also highlighting the potential for future growth. Although the grade suggests that while Sutro has not achieved top-tier standing, it exhibits the foundational elements necessary for investors to consider its long-term prospects.
[chart type=’st-cards’ value=’STRO’]
Conclusion
Sutro Biopharma, Inc. (STRO) offers a compelling narrative for investors looking at high-risk, high-reward opportunities. The upgrade from Wedbush to an “Outperform” rating, coupled with a considerable upside to the price target, positions this stock as more than just a speculative play. However, the historical volatility and past performance underscore the risks involved, suggesting that this stock may suit more adventurous investors focused on potential long-term growth rather than those seeking stability. Continued scrutiny of earnings patterns and analyst sentiment will be crucial as investors watch for further developments in Sutro’s journey.